Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Hepatitis C treatment
Moving on with my life: Getting cured of hepatitis C

Interviews with people who have had successful treatment for hepatitis C & what it means for them. Made for the annual conference of the London Joint Working Group on Substance Use & Hepatitis C, Held at The Guildhall London on 3 December 2018.

Published
07 December 2018
From
YouTube
Hepatitis C treatment
Eliminating Hepatitis: A unique opportunity that shouldn't be missed

Micro-elimination seeks to eliminate HCV in particular target populations, permitting rapid, focused action. It can also address inequities in service delivery by concentrating health system attention on stigmatised groups. Initiatives aimed at specific risk groups, such as men who have sex with men, migrants and drug users, already exist for HIV in so-called ‘Fast-Track’ cities, such as Amsterdam and Madrid and need to be adapted to include hepatitis.

Published
22 November 2018
From
The Parliament Magazine
Hepatitis C treatment
Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

Published
15 October 2018
From
Healio
Hepatitis C treatment
Anti-virals cure up to 98% of hepatitis C patients since 2014

The figures from the national treatment registry for Irish hepatitis C patients represent “a triumph of science”, Dr Diarmuid Houlihan, a hepatologist at St Vincent’s University Hospital told a conference in Dublin on Monday.

Published
09 October 2018
From
Irish Times
Pharmaceutical industry
What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large drug and biotech companies have done so in recent years, and this is what is being seen at Gilead Sciences Inc.

Published
25 September 2018
From
24/7 Wall St.
Pharmaceutical industry
Gilead to launch generic versions of its hepatitis drugs

Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Published
25 September 2018
From
Reuters
Access to medicines and treatment
Brazil court strips Gilead hepatitis drug patent, politician says

A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

Published
25 September 2018
From
Reuters
Hepatitis C treatment
Overwhelming evidence shows hepatitis C treatment effective for people who inject drugs

Researchers are calling on an end to discriminatory health and illicit drugs policies, based on overwhelming evidence that new hepatitis C therapies are effective at curing the virus in people who inject drugs.

Published
21 September 2018
From
EurekAlert
Pharmaceutical industry
EPO Upholds Gilead Patent On Hep C Medicines, But In Amended Form

The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained in an amended form. Civil society involved in the case expressed dismay over the outcome and its potential effect on European drug prices.

Published
16 September 2018
From
Intellectual Property Watch
Pharmaceutical industry
Groups Call for End to Gilead’s Unwarranted Hepatitis C Drug Monopoly in Europe

This week in Munich, the European Patent Office (EPO) will hear a legal challenge filed by groups in 17 countries against an unmerited patent that allows US-based pharmaceutical corporation Gilead Sciences to charge exorbitant prices in Europe for the key hepatitis C drug sofosbuvir.

Published
11 September 2018
From
MSF press release
← Prev12345...75Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.